Literature DB >> 16006188

New insights into clostridial neurotoxin-SNARE interactions.

Mark A Breidenbach1, Axel T Brunger.   

Abstract

Botulinum neurotoxin serotype A (BoNT/A) has achieved a dichotomous status in modern medicine; it is both a versatile treatment for several neurological disorders and a lethal poison responsible for causing the neuroparalytic syndrome botulism. The extent of paralysis largely depends on the dosage of toxin received. The toxins block neurotransmitter release by delivering their Zn(2+)-dependent protease components to the presynaptic side of chemical synapses. These highly specialized enzymes exclusively hydrolyze peptide bonds within SNARE (soluble N-ethylmaleiamide-sensitive factor attachment protein receptor) proteins. Recently, the structural basis for the highly specific interaction between BoNT/A and its target SNARE, SNAP-25 (synaptosomal-associated protein of 25kDa), was elucidated. New details regarding the nature of the toxin-SNARE interactions could be exploited for novel inhibitor design.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16006188     DOI: 10.1016/j.molmed.2005.06.012

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  24 in total

1.  High-level expression, purification, crystallization and preliminary X-ray crystallographic studies of the receptor-binding domain of botulinum neurotoxin serotype D.

Authors:  Yanfeng Zhang; Xiaoli Gao; Ling Qin; Garry W Buchko; Howard Robinson; Susan M Varnum
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-11-25

2.  Molecular basis of activation of endopeptidase activity of botulinum neurotoxin type E.

Authors:  Roshan V Kukreja; Shashi K Sharma; Bal Ram Singh
Journal:  Biochemistry       Date:  2010-03-23       Impact factor: 3.162

3.  A yeast assay probes the interaction between botulinum neurotoxin serotype B and its SNARE substrate.

Authors:  Hong Fang; Wentian Luo; Jim Henkel; Joseph Barbieri; Neil Green
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

4.  High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.

Authors:  Matthew J Saunders; Steven W Graves; Larry A Sklar; Tudor I Oprea; Bruce S Edwards
Journal:  Assay Drug Dev Technol       Date:  2010-02       Impact factor: 1.738

5.  Vesicle-associated membrane protein (VAMP) cleavage by a new metalloprotease from the Brazilian scorpion Tityus serrulatus.

Authors:  Paul L Fletcher; Maryann D Fletcher; Keith Weninger; Trevor E Anderson; Brian M Martin
Journal:  J Biol Chem       Date:  2009-12-21       Impact factor: 5.157

6.  Structural analysis of the receptor binding domain of botulinum neurotoxin serotype D.

Authors:  Yanfeng Zhang; Garry W Buchko; Ling Qin; Howard Robinson; Susan M Varnum
Journal:  Biochem Biophys Res Commun       Date:  2010-09-19       Impact factor: 3.575

7.  Botulinum Toxin: Non-cosmetic Indications and Possible Mechanisms of Action.

Authors:  Uwe Wollina
Journal:  J Cutan Aesthet Surg       Date:  2008-01

8.  Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.

Authors:  Jorge E Zuniga; Jared T Hammill; Omri Drory; Jonathan E Nuss; James C Burnett; Rick Gussio; Peter Wipf; Sina Bavari; Axel T Brunger
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

Review 9.  Facial rejuvenation for middle-aged women: a combined approach with minimally invasive procedures.

Authors:  Alberto Goldman; Uwe Wollina
Journal:  Clin Interv Aging       Date:  2010-09-23       Impact factor: 4.458

Review 10.  Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.

Authors:  Michael B Chancellor; Clare J Fowler; Apostolos Apostolidis; William C de Groat; Christopher P Smith; George T Somogyi; K Roger Aoki
Journal:  Nat Clin Pract Urol       Date:  2008-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.